Comprehensive real-time epidemiological data from respiratory infections in Finland between 2010 and 2014 obtained from an automated and multianalyte mariPOC (R) respiratory pathogen test by Gunell, M. et al.
ORIGINAL ARTICLE
Comprehensive real-time epidemiological data from respiratory
infections in Finland between 2010 and 2014 obtained
from an automated and multianalyte mariPOC® respiratory
pathogen test
M. Gunell1,2 & P. Antikainen3 & N. Porjo3 & K. Irjala4 & J. Vakkila4 & K. Hotakainen4,5 &
S. S. Kaukoranta6 & J. J. Hirvonen6 & K. Saha7 & R. Manninen8 & B. Forsblom9 &
K. Rantakokko-Jalava2 & V. Peltola10 & J. O. Koskinen3 & P. Huovinen1
Received: 4 November 2015 /Accepted: 7 December 2015 /Published online: 6 January 2016
# Springer-Verlag Berlin Heidelberg 2015
Abstract Respiratory viruses cause seasonal epidemics every
year. Several respiratory pathogens are circulating simulta-
neously and typical symptoms of different respiratory infec-
tions are alike, meaning it is challenging to identify and diag-
nose different respiratory pathogens based on symptoms
alone. mariPOC® is an automated, multianalyte antigen test
which allows the rapid detection of nine respiratory infection
pathogens [influenza A and B viruses, respiratory syncytial
virus (RSV), human metapneumovirus, adenovirus,
parainfluenza 1–3 viruses and pneumococci] from a single
nasopharyngeal swab or aspirate samples, and, in addition,
can be linked to laboratory information systems. During the
study period from November 2010 to June 2014, a total of 22,
485 multianalyte respi tests were performed in the 14 partici-
pating laboratories in Finland and, in total, 6897 positive an-
alyte results were recorded. Of the tested samples, 25 % were
positive for one respiratory pathogen, with RSV (9.8 %) and
influenza A virus (7.2 %) being the most common findings,
and 0.65 % of the samples were multivirus-positive. Only
small geographical variations in seasonal epidemics occurred.
Our results show that the mariPOC® multianalyte respi test
allows simultaneous detection of several respiratory patho-
gens in real time. The results are reliable and give the clinician
a picture of the current epidemiological situation, thus
minimising guesswork.
Introduction
Every year, respiratory viruses cause seasonal epidemics. In
Northern Europe, the epidemic season starts in September–
October and lasts until April. Since several respiratory patho-
gens are circulating at the same time and typical symptoms of
different respiratory infections (cough, fever, rhinitis, head-
ache etc.) are quite similar, it can be difficult to identify and
diagnose different pathogens based on symptoms alone. To be
able to avoid unnecessary antimicrobial treatment and to focus
antiviral treatment properly, rapid and reliable detection of
respiratory pathogens is needed. At the moment, verified viral
results in Finland are reported to the Register for Infectious
Diseases of the National Institute for Health and Welfare
(NIHW, http://www.thl.fi/ttr/gen/rpt/tilastot.html, [1]). Data
from this national register go to The European Surveillance
System (TESSy), a data bank organised by the European
Centre for Disease Prevention and Control (ECDC, [2]), and
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these European-wide data are further combined with data col-
lected all over the world by the World Health Organization
(WHO, [3]). After the data are collected, they need to be
analysed and further processed into reports, and this can take
1–2 weeks. Thus, although these reports are extensive and
usually rapidly and widely available in electronic format, the
data themselves have already expired. In addition, at least in
Finland, the data do not represent the outpatient setting, but
hospitalised patients and military recruits. New rapid and au-
tomated multianalyte tests could potentially help to provide
more accurate and real-time data to help health care profes-
sionals in infection management and containment, especially
in outpatient settings.
mariPOC® (ArcDia International Oy Ltd, Turku, Finland)
is an automated, multianalyte antigen test for the rapid detec-
tion of respiratory infection pathogens from a single nasopha-
ryngeal swab or aspirate sample [4, 5]. The mariPOC® respi
test allows the detection of nine clinically relevant pathogens
from the upper and lower respiratory tracts. The test panel
includes: influenza A and B viruses (IAVand IBV), respirato-
ry syncytial virus (RSV), human metapneumovirus (hMPV),
adenovirus (AdV), parainfluenza 1–3 viruses (PIV 1, 2, 3) and
Streptococcus pneumoniae. The automated mariPOC®
analyser has been designed for point-of-care use and it can
be connected to laboratory information systems (LIS). The
majority (75 %) of positive results are reported within
20 min, while final results are reported after 2 h for low pos-
itive and negative samples.
The aim of our study was to investigate and analyse the
epidemiological data of respiratory pathogens in Finland re-
corded by the mariPOC® respiratory tests during the seasonal
epidemics between November 2010 and June 2014. In addi-
tion, the benefits of using the mariPOC® multianalyte test in
rapid diagnostics and in collecting epidemiological data, for
doctors and for patients, are discussed.
Materials and methods
Specimen collection
The nasopharyngeal swab samples and aspirates for
mariPOC® analyses were collected in 14 hospitals and private
health care centres in different parts of Finland: Oulu, Vaasa,
Seinäjoki, Pori, Turku, Tampere, Espoo, Helsinki, Vantaa,
Kotka and Kouvola (Fig. 1). mariPOC® tests performed be-
tween week 48 in 2010, i.e. at the beginning of the seasonal
epidemic, and week 24 in 2014 were included in this study.
During the first respiratory virus season, the only participant
was Satakunta Central Hospital (Pori). The majority of labo-
ratories started to analyse samples at the beginning of the
epidemic season 2011–2012, and continued until the end of
season 2014 (Fig. 2). Samples were taken from patients
suffering from typical symptoms of respiratory tract infection,
whenever aetiological diagnostics was considered necessary
by the attending physician. Nasopharyngeal swab samples
were collected and handled as previously described [4, 5].
This study was performed retrospectively, based on epidemi-
ological data collected as part of routine diagnostic procedures
and, therefore did not require any ethical committee approval.
Patient data were not handled in any way.
mariPOC® rapid antigen detection
The mariPOC® platform (ArcDia International Oy Ltd, Tur-
ku, Finland) is based on a two-photon fluorescence excitation
detection technique, where micro-volume immunometric an-
tigen detection is performed in a separation-free assay format
[6, 7]. mariPOC® is a fully automated system, allowing
random-access analysis. Preliminary results are automatically
reported after 20 min. Samples were analysed with the
mariPOC® respi test according to the instructions for use. It
was used in various different types of clinical units, including
point-of-care use by nurses where tests were done 24/7, pri-
vate health care clinics, and clinical microbiology and clinical
chemistry emergency laboratories, where tests were per-
formed by biomedical lab nurses.
mariPOC® data collection
Epidemiological data were collected by the remote access ser-
vice of the test system. This allows simultaneous and retro-
spective analysis of the data recorded by all mariPOC® users.
Both site-specific data and various combinations were
analysed. The incidence of viruses recorded by mariPOC®
was compared to the surveillance data collected by the virol-
ogy unit of the NIHW. The total number of performed
mariPOC® tests and the number of positive results for each
tested respiratory pathogen were downloaded from participat-
ing laboratories on a weekly basis by ArcDia’s personnel.
Results
Respiratory pathogen results
During the study period from November 2010 to June 2014, a
total of 22,485 multianalyte respi tests were performed in the
14 participating laboratories and a total of 6897 positive ana-
lyte results were recorded. A summary of the positive samples
recorded by the mariPOC® respi test is shown in Fig. 3. Three
clear epidemiological peaks were detected in the second
(2011–2012) to fourth (2013–2014) seasonal respiratory path-
ogen epidemics. During the first annual epidemic, 2010–2011,
only one unit participated in this study and 475 tests were
performed. The peak in testing was detected at week 10/
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2011, when 68 samples were tested and nine of these were
influenza B virus positive. Also, a small RSV peak (eight
positive samples) was detected at week 15/2011.
RSVand IAV were the most commonly detected respirato-
ry viruses included in the test panel in Finland during the study
period. Ten percent of the tested samples were positive for
RSVand 7 % for IAV (Table 1). During the annual epidemics,
equal amounts of positive IAVand RSV findings were detect-
ed. The proportion and the number of positive IAV and RSV
findings were highest during the 2011–2012 epidemic
Fig. 1 Finnish health care centres
and hospitals participating in this
study
Fig. 2 The time span for
mariPOC® respi test data
collection from different units in
Finland
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(Table 2). The annual epidemiological peaks of RSVand IAV
also occurred almost simultaneously, RSV a few weeks later
than IAV (Table 2 and Fig. 3).
Other respiratory pathogens included in the mariPOC®
respi test panel were found less frequently, except IBV and
hMPV, of which larger epidemics were seen during the winter
of 2013 (Table 2 and Fig. 3). Pneumococci were the second
most common respiratory pathogen detected (Table 1). Three
distinct peaks for pneumococci were detected during the an-
nual epidemics (Table 2). However, samples positive for
pneumococci were also detected outside the seasonal epi-
demics, especially in late summer to early fall (weeks 29–
41) in 2012, when 14% (78/577) of the samples were positive
for pneumococci (Fig. 3).
A total of 6150 (27%) patient samples were positive for the
respiratory pathogens included in the mariPOC® respi test
panel. During the seasonal epidemics, up to 44–58 % of the
samples were positive for at least one respiratory pathogen
(Fig. 4). Excluding pneumococci (due to the substantially high
carriage rate [8]), viral co-infection was detected among
0.65 % of the tested samples (3 % of the positive samples,
n=146). Of these, 67% (n=98) were positive for two viruses.
RSV was the most common virus present in co-infections: it
was found in 70 % of two-virus infections, in 61 % of infec-
tions with three viruses and in 100 % of the findings positive
for four viruses. RSV/IAV co-infection was the most common
combination (n=26), followed by RSV/PIV1 (n=12), RSV/
PIV3 (n=7) and RSV/hMPV (n=6) combinations.
Epidemiological peaks of different respiratory pathogens
varied annually. During the 2011–2012 epidemic, the highest
incidences of IAV, RSV, pneumococci and hMPV were de-
tected simultaneously at week 7, whereas during the 2012–
2013 epidemic, peaks in the positive findings of different re-
spiratory pathogens varied from week 6 (hMPV) to week 12
Fig. 3 The numbers of positive
respiratory pathogen results in
Finland between 2011 and 2014,
detected with the mariPOC® respi
test
Table 1 The number and
proportions of positive results,
and the proportions of different
respiratory pathogens among all
positive findings recorded by the
mariPOC® respi test during the
study period
Respiratory pathogen No. of positive findings
(% of tested)
No. of tested
samples
Proportion of all
positive findings
Respiratory syncytial virus 2197 (9.8) 22,422 32 %
Pneumococci 1456 (9.4) 15,559 21 %
Influenza A virus 1625 (7.2) 22,420 24 %
Influenza B virus 489 (2.2) 22,324 7 %
Human metapneumovirus 386 (1.7) 22,354 6 %
Parainfluenza virus 3 280 (1.3) 22,298 4 %
Adenovirus 219 (1.0) 22,309 3 %
Parainfluenza virus 1 151 (0.7) 22,259 2 %
Parainfluenza virus 2 94 (0.4) 22,263 1 %
Total 6897 (30.7) 22,485 100 %
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(RSV). A wide variation in the incidence of respiratory path-
ogens was also seen during the 2013–2014 annual epidemic
(Table 2 and Fig. 3).
Geographical variation
mariPOC® respi test results from different laboratories partic-
ipating in this study were also analysed by dividing units into
geographical areas: Western Finland (Satakunta Central Hos-
pital, Vaasa Central Hospital and Southern Ostrobothnia
Central Hospital), South-West Finland (Mehiläinen Turku,
TYKSLab and Department of Pediatrics/Turku University
Hospital), Southern Finland (Mehiläinen Espoo, Vantaa and
Töölö; Diacor Espoo) and South-East Finland (Kuusankoski
Regional Hospital and Kymenlaakso Central Hospital). Small
variations in prevalence and epidemiological peaks of differ-
ent respiratory viruses were seen. In our study, RSV was the
most commonly detected respiratory virus, and IAV was more
prevalent only in South-East Finland during the 2012–2013
and 2013–2014 epidemics (Fig. 5a, b). During the 2011–2012
Table 2 Annual epidemiological
peaks, and the number and
proportion of positive respiratory
syncytial virus (RSV),
pneumococcal, influenza A and B
viruses (IAVand IBV) and human
metapneumovirus (hMPV)
findings during the
epidemiological peaks
Respiratory pathogen Epidemiological peak (week) No. of positive findings (%)
RSV 7/2012 97 (21)
12/2013 56 (16)
10/2014 76 (16)
14/2014 76 (24)
Pneumococci 7/2012 42 (16)
9/2013 35 (11)
8/2014 38 (9)
IAV 7/2012 91 (20)
10/2013 66 (16)
8/2014 87 (15)
IBV 15/2012 6 (3)
16/2012 6 (3)
7/2013 29 (8)
6/2014 13 (3)
hMPV 7/2012 11 (2)
6/2013 25 (8)
16/2014 10 (4)
17/2014 10 (4)
Fig. 4 The number of tested
samples compared with the
percentage of positive results,
detected with the mariPOC® respi
test
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annual epidemic, RSV and IAV peaks were detected almost
simultaneously at week 7/2012. During the 2012–2013 annual
epidemic, the RSV peak in Southern Finland had occurred
already in week 5/2013, 7–9 weeks earlier than in other areas,
whereas the IAV epidemic occurred almost simultaneously,
between weeks 6–10/2013. During the 2013–2014 annual ep-
idemic, IAVand RSV peaks arrived in adjacent weeks (7 and
8/2014) in Southern Finland, whereas in other parts of Fin-
land, the IAV peak came 3 to 5 weeks earlier than the RSV
peak (Fig. 5a, b). Geographically, a wider variation was seen
in the RSVannual epidemiological peak compared to the IAV
peak. RSV epidemics also lasted longer than IAV epidemics,
and broader peaks were detected especially on the west coast
of Finland (Fig. 5b). In early 2013, there was also a small IBV
epidemic in Western Finland, which was detected in week 8/
2013, simultaneously with the IAV peak (Fig. 3).
Frequency of testing versus positive findings
During the seasonal epidemics, the number of performed re-
spiratory tests was eight times higher compared to tests per-
formed outside the epidemic season. In Fig. 5, the three-week
running average of the number of analysed samples and the
proportion of positive samples are presented. Despite the fluc-
tuation in the proportion of positive findings, especially out-
side the epidemics, the highest numbers of positive findings
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Fig. 5 Influenza A virus (IAV, a) and respiratory syncytial virus (RSV, b) epidemics in different parts of Finland
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were detected during the epidemiological peaks, when respi-
ratory pathogens are circulating abundantly. It also shows that
a peak in testing appears at the same time (weeks 8 and 9) in
different years (2012–2014), whereas the peak in the propor-
tion of positive samples varied between different years: in
2012, the epidemiological peak was 1 week ahead of the test-
ing peak; in 2013, there were two distinct epidemiological
peaks and the testing peak hit in the middle of these peaks;
and in 2014, the testing peak was actually 5 weeks ahead of
the epidemiological peak (Fig. 4).
Respiratory pathogen epidemics occurred simultaneously
all over Finland during the 2011–2012 and 2013–2014 annual
epidemics. However, during the 2012–2013 epidemic, a var-
iation between different geographic areas was seen, when a
peak in testing was detected at week 6 in Southern Finland,
week 9 in Western Finland, week 10 in South-East Finland
and as late as week 16 in South-West Finland. A comparison
of the positive results with the number of tested samples
showed that the relative proportion of positive IAV and RSV
samples correlated with the number of positive findings per
week. During the seasonal epidemics, the percentage of IAV-
and RSV-positive samples were up to 20 and 25 % of the
tested samples, respectively, and outside the epidemics, the
percentage of positive samples was less than 5 %. The per-
centage of findings positive for pneumococci remained the
same, approximately 10 %, during the whole study period.
Discussion
The mariPOC® respi test is a rapid and validated test methodol-
ogy for respiratory pathogens: more than half of the positive
results are obtained within 20 min and the final results within
2 h, with sensitivities for influenza viruses and RSVof 80–90 %
and analytical specificities ≥99 %, on average [4, 5]. The
mariPOC® respi test preliminary results at 20 min showed
99.9 % analytical specificity, and, on average, a maximum 1
out of 100 tested samples gives a false-positive result. A positive
preliminary result is true in 97 % of cases, on average. For IAV,
the positive predictive value is up to 97.8%, and for RSV 99.1%
(data not shown). Negative fluorescence readouts (results) are not
reported in the preliminary phase, since some may turn positive
in the 2 h that it takes for the assay to reach equilibrium. Never-
theless, the negative predictive value of the preliminary results
(no results shown) is 98 %, indicating that most of the prelimi-
nary negatives remain negative for that particular analyte also
after 2 h. Typically, POC tests are rapid, but less sensitive than
polymerase chain reaction (PCR)-based methods. However,
mariPOC® antigen detection has shown good sensitivity, espe-
cially in the detection of influenza viruses and RSVand group A
Streptococcus, and the specificities of all methods have been
excellent [4, 5, 9]. Ivaska et al. reported that mariPOC® had, in
their study, only a moderate sensitivity for AdV and hMPV
compared to PCR, but also noted that, sometimes, DNA/RNA
findings by PCR may be clinically non-relevant [4]. Thus, PCR
methods can be sometimes even too sensitive.
The LIS feature allows a rapid diagnosis, accurate reporting
of results and data storage, and use of the results in real-time.
This real-time epidemiological data can be a beneficial tool for
health care professionals; based on the local epidemiology of
circulating respiratory pathogens, testing procedures can be
optimised based on real knowledge on what and when certain
respiratory pathogens should be tested and, therefore, diagno-
ses can be made more accurately. Sharing this information
with patients might make it easier for doctors to justify not
prescribing antibiotics. Mehiläinen, a country-wide private
health care provider in Finland, already has such a tool, where
positive virus results and the numbers of tests performed in the
laboratory are updated on a daily basis, and the epidemiolog-
ical trend is presented in real time to their clinicians and lab-
oratories all over the country.
The introduction of mariPOC® respi testing in Finland has
significantly increased the number of tests performed, and has
enabled pathogen-specific diagnosis, especially for viruses for
which no other rapid multianalyte tests are available. Individ-
ual users may run 1000–2000 tests a year, a magnitude similar
to that reported by official national epidemiological follow-up
systems (e.g. the NIHW). Thus, potentially available epidemi-
ological data have reached completely new levels, and this
should be put into use more efficiently for real-time epidemi-
ological surveillance. In contrast to conventional rapid assays,
the mariPOC® technique is characterised by an automated
results readout. Thus, the analysers could be connected not
only to LIS but also via the internet to a national or global
database and surveillance system, allowing health care author-
ities to monitor ongoing infections online. Such a surveillance
system would support the control of infectious diseases and
epidemics, and provide an ‘early warning’ system for changes
in pathogen activities [10–12]. Influenza virus, for example,
causes milder disease before the epidemic peak arrives. Once
the number of positive cases increases, the incidence and pro-
portion of more severe diseases also increase [13]. This would
have a high impact both for the individual and for society.
Our results show that, within the limits of the test’s sensi-
tivities, all the respiratory pathogens included in the
mariPOC® respi test panel were detected, although a wide
variation in frequencies was seen. Our study shows that
RSV (10 %) and IAV (7%) were the most commonly detected
viruses in Finland during the whole study period, whereas
other tested viruses (AdV, IBV, PIV 1–3 and hMPV) were
found only in small proportions (<2 %). Although the test’s
slightly variable sensitivity against different viruses might
have some impact on the results, the epidemiological picture
produced by the mariPOC® respi test was well in line with
virus results reported from the virology unit at the NIHW.
Proportions of AdV and IBV findings detected with
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mariPOC® were the same size as those reported in the Regis-
ter for Infectious Diseases of the NIHW (http://www.thl.fi/ttr/
gen/rpt/tilastot.html). When IAV and RSV results are
compared, RSV is detected more frequently with
mariPOC®, whereas higher numbers of IAV are reported in
the NIHW register compared to RSV (data not shown).
However, the NIHW register is currently updated only
monthly, although the data is collected on a weekly basis;
thus, it is retrospective and does not provide the current
clinical situation. In contrast, mariPOC® provides real-time
data also for end-point users, i.e. clinicians.Moreover, the data
for the NIHW register are collected from hospitals and garri-
sons and, therefore, do not reflect the epidemiological situa-
tion in the population visiting health care centres in Finland.
Our data include probably more samples from child patients
compared to the NIHW register.
The number of participating laboratories increased during
the study, and the number of tested samples varied between
the annual epidemics. It is notable that the highest numbers of
positive findings were detected already in 2012 at week 7,
when only seven out of 14 units participated in this study
(Fig. 2); thus, the 2011–2012 seasonal epidemic was actually
more severe than the following epidemics. Our results show
that the seasonal epidemics of respiratory pathogens start al-
most simultaneously all over Finland, and only slight varia-
tions in epidemiological peaks were detected geographically.
Our geographically divided data also showed that the preva-
lence of different pathogens varied between different areas.
For example, no clear RSV peak was detected in South-
Eastern Finland, and the IBV epidemic in 2013 was concen-
trated in Southern Finland. In Northern Europe, IAV epi-
demics are concentrated in the winter months, and the peak
is usually in February [14]. RSV epidemics occur simulta-
neously with IAV, and the peak is in February, but with a wider
time span [14, 15]. Our results were in concordance with these
reports: the IAV peak was commonly detected between weeks
7 and 9, whereas the annual RSV peak had a wider range
(from week 7 in 2012 to week 14 in 2014). Minor geograph-
ical differences were also detected: in South-Eastern Finland,
RSV epidemics were smaller, and in Southern Finland, the
2013 epidemiological peak was detected already at week 5.
We have shown in this study that 27 % of all the tested
nasopharyngeal swabs were positive for at least one of the
respiratory pathogens included in the mariPOC® respi test
and, during the epidemics, the percentage was even higher.
Samples were taken from patients suffering from symptoms
of respiratory infection; thus, the patients with a sample neg-
ative for the tested viruses probably had some other respirato-
ry virus. For example, rhinovirus, which is the predominant
cause of common cold, coronaviruses, which are a significant
cause of common cold in adults, human bocavirus, which
might cause lower respiratory tract infections and non-polio
enteroviruses, which can cause mild respiratory symptoms,
circulate at the same time as the pathogens currently included
in the mariPOC® respi test panel [16–18]. Since the sensitivity
of any rapid POC immunoassay test can hardly be 100 %,
some positive cases have supposedly gone undetected. Based
on the previous studies, this fraction may be expected to be
10–20 % with mariPOC® [4, 9].
Our results show that the percentage of positive findings
followed the seasonal epidemiology. During the epidemics,
the number of positive findings was highest, but also the pro-
portion of positive findings increased, indicating a real epide-
miological event. This also indicates that the testing for respi-
ratory viruses, especially IAVand RSV, is correctly scheduled.
During off-season, between May and October, only sporadic
infections are encountered, and only 1.4 % of tested samples
are positive. Findings positive for pneumococci did not follow
the seasonal epidemics, and the percentage of positive find-
ings, 10%, can signify carriage: 5–10% of adult and >30% of
child patients have been reported to be carriers of pneumococ-
ci [8, 19].
It is commonly known that the annual circulation of differ-
ent respiratory pathogens follow a certain pattern. For exam-
ple, IAV and RSV circulation shows a wave-like pattern,
whereas adenovirus is present throughout the year. It is also
commonly known that RSV causes larger epidemics biannu-
ally [15, 20], which could also be seen in our material: RSV
was detected more frequently in samples in 2012 and 2014
compared to 2013 (Table 2 and Fig. 3). Based on these com-
monly known patterns for respiratory virus circulation, clini-
cians probably use this ‘educated guess’ when they order lab-
oratory tests for their patients. However, this educated guess
can also cause bias: if RSV is tested more often every other
year, it can be expected to be found more frequently. If the
mariPOC® multianalyte test is used, this forethought has no
impact on results. With multianalyte testing, it is possible to
get results on several pathogens simultaneously, and although
the swab might have been taken to assure RSV positivity, the
result might show that the patient actually has an adenovirus
or an RSV–pneumococcal co-infection. Our results show that
viral co-infection was detected among 0.65 % of the tested
samples (3 % of the positive samples), and 67% of these were
double infections, with RSV being the most common virus
present in co-infections. Thus, mariPOC® detects and reports
the actual epidemiological situation of respiratory pathogens.
In conclusion, this is the first comprehensive study of re-
spiratory virus epidemiology in Finland. We have shown that,
with the mariPOC®multianalyte respi test, several respiratory
pathogens could be detected in real time, and the results were
reliable and reflected the true epidemiological situation, not
only common expectations. Seasonal epidemics of respiratory
pathogens occurred simultaneously all over Finland, with
small geographical variations, and RSV and IAV were the
most common viruses in Finland, as detected with the
mariPOC® respi test.
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